BIIB
NasdaqBIOGEN INC.
Health Care, Biotechnology
$207.94
close 7 Aug 2026
+62.45%
52-week change
$30.70B
market cap
$127.71
$219.72
52-week range
| Line item | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 | FY07 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | ||||||||||||||||||||
| Revenue | $9.94B | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B | $13.44B | $14.38B | $13.45B | $12.27B | $11.45B | $10.76B | $9.70B | $6.93B | $5.52B | $5.05B | $4.72B | $4.38B | $4.10B | $3.17B |
| Cost of revenue | $2.44B | $2.40B | $2.31B | $2.53B | $2.28B | $2.11B | $1.81B | $1.96B | $1.82B | $1.63B | $1.48B | $1.24B | $1.17B | $857.70M | $545.49M | $466.78M | $400.26M | $382.10M | $401.99M | $335.19M |
| Gross profit | — | — | — | — | — | — | $11.64B | $12.42B | $11.64B | $10.64B | $9.97B | $9.52B | $8.53B | $6.07B | $4.97B | $4.58B | $4.32B | $4.00B | — | — |
| R&D | $1.88B | $1.78B | $1.98B | $2.45B | $2.23B | $2.50B | $3.99B | $2.28B | $2.60B | $2.25B | $1.97B | $2.01B | $1.89B | $1.44B | $1.33B | $1.22B | $1.25B | $1.28B | $1.07B | $925.16M |
| SG&A | $2.47B | $2.43B | $2.40B | $2.55B | $2.40B | $2.67B | $2.50B | $2.37B | $2.11B | $1.93B | $1.95B | $2.11B | $2.23B | $1.71B | $1.28B | $1.06B | $1.03B | $911.03M | $925.31M | $776.10M |
| Operating income | — | — | — | — | — | $2.84B | $4.55B | $7.04B | $5.89B | $5.35B | $5.15B | $4.89B | $3.97B | $2.52B | $1.86B | $1.72B | $1.25B | $1.30B | $1.21B | $779.77M |
| Interest expense | $275.10M | $267.50M | $250.30M | $246.90M | $246.60M | $253.60M | $222.50M | $187.40M | $200.60M | $250.80M | $260.00M | $95.50M | $29.50M | $31.90M | $36.50M | $33.00M | $36.10M | $35.80M | $52.00M | — |
| Tax expense | $251.10M | $263.60M | $273.80M | $135.30M | $632.80M | $52.50M | $992.30M | $1.16B | $1.43B | $2.46B | $1.24B | $1.16B | $989.90M | $601.00M | $470.55M | $444.53M | $331.33M | $355.62M | $365.78M | $272.42M |
| Net income | $1.37B | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B | $4.00B | $5.89B | $4.43B | $2.54B | $3.70B | $3.55B | $2.93B | $1.86B | $1.38B | $1.23B | $1.01B | $970.13M | $783.17M | $638.17M |
| Diluted EPS | $9.30 | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 | $24.80 | $31.42 | $21.58 | $11.92 | $16.93 | $15.34 | $12.37 | $7.81 | $5.76 | $5.04 | $3.94 | $3.35 | $2.65 | $1.99 |
| Gross margin | — | — | — | — | — | — | 86.57% | 86.40% | 86.50% | 86.72% | 87.08% | 88.48% | 87.93% | 87.63% | 90.11% | 90.76% | 91.51% | 91.27% | — | — |
| Operating margin | — | — | — | — | — | 25.87% | 33.84% | 48.98% | 43.77% | 43.55% | 45.00% | 45.44% | 40.94% | 36.29% | 33.64% | 34.16% | 26.48% | 29.59% | 29.62% | 24.59% |
| Net margin | 13.81% | 13.07% | 16.87% | 11.81% | 29.95% | 14.17% | 29.76% | 40.96% | 32.93% | 20.69% | 32.34% | 32.95% | 30.25% | 26.86% | 25.02% | 24.45% | 21.31% | 22.16% | 19.11% | 20.12% |
filed 29 Apr 2026